Background. Erythromycin is largely employed in acne therapy both for its activity in reducing P.Acnes number and antinflammatory potential. Unfortunately antibiotic resistant strains of P. acnes progressively developped. Is has been observed that the association of erythromycin with other pharmacologically active molecules may increase its clinical efficacy and reduce the production of resistant strains. Methods. In this split-face study 20 acne patients have been treated concurrently with two topical antiacne treatments. The first one was an association of erythromycin 3% and isotretinoin 0.05% gel and the second one erythromycin 3% and zinc lotion. Tolerability and clinical efficacy of the drugs have been evaluated. Results. Statistical analysis revealed no relevant differences between the two drugs according to the reduction in number of inflammatory, non-inflammatory and total lesions. Frequence and entity of side effects were not different comparing the two treatments. Conclusions. On the basis of the results of the study, it could be concluded that both these antiacne drugs are useful in terms of clinical efficacy. From the tolerability point of view they appeared to be safe and cosmetically well accepted.
|Translated title of the contribution||Erythromycin 2% + isotretinoin 0.05% gel vs erythromycin 3% + zinc lotion: Comparative split-face evaluation of efficacy and tolerability in acne patients|
|Number of pages||6|
|Journal||Giornale Italiano di Dermatologia e Venereologia|
|Publication status||Published - 2002|
ASJC Scopus subject areas